TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34838518

Group type: EXPERIMENTAL
Intervention: CRT in Asian patients with QRSd <150 ms (n=71)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: CRT in Asian patients with QRSd ≥150 ms (n=180)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Overall CRT response in Asians (n=251)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Heart failure events and cardiac deaths in Asians
Number of subjects: 934

Group type: COMPARATOR
Intervention: CRT response in non-Asian patients with QRSd <150 ms (n=248)
Number of subjects: 934

Group type: COMPARATOR
Intervention: CRT response in non-Asian patients with QRSd ≥150 ms (n=435)
Number of subjects: 934
Study: 34838717

Group type: EXPERIMENTAL
Intervention: Oral HPV prevalence measured using a commercially available PCR DNA test.
Number of subjects: 7877

Group type: EXPERIMENTAL
Intervention: Follow-up every 6 months for 24 months in the US.
Number of subjects: 7877
Study: 34838718

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34839011

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) in PD patients (PD + RS)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Resistant Starch (RS) in control subjects
Number of subjects: 87

Group type: COMPARATOR
Intervention: Dietary instructions in PD patients
Number of subjects: 87
Study: 34839054

Group type: EXPERIMENTAL
Intervention: Decitabine followed by rapamycin (10 days of decitabine followed by 12 days of rapamycin in cycle 1 and 5 days of decitabine followed by 17 days of rapamycin in subsequent cycles)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Decitabine alone (historical control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Decitabine followed by rapamycin (in de novo group)
Number of subjects: 24
Study: 34839055

Group type: EXPERIMENTAL
Intervention: Home-based intensive chemotherapy
Number of subjects: 104
Study: 34839060

Group type: EXPERIMENTAL
Intervention: Cerene cryotherapy device
Number of subjects: 230
Study: 34839199

Group type: EXPERIMENTAL
Intervention: EMI-137 (0.13 mg/kg) administered intravenously 1-3 hours before surgery
Number of subjects: 9
Study: 34839196

Group type: EXPERIMENTAL
Intervention: Parenting stress at hospital discharge
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Education at hospital discharge
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Infant's medication number at hospital discharge
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Insurance type at hospital discharge
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Medications number at hospital discharge
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Tube-assisted feeding at hospital discharge
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Parenting stress at 4 months
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ethnicity at 4 months
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Number of ED visits at 4 months
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cardiologist visits at 4 months
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Single ventricle physiology at 4 months
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Number of children at 4 months
Number of subjects: 158
Study: 34839268

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 167

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 167
Study: 34839425

Group type: EXPERIMENTAL
Intervention: Immediate Breast Reconstruction (IBR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Delayed Breast Reconstruction (DBR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Autologous Flap Reconstruction
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Implant Reconstruction
Number of subjects: 38
Study: 34839447

Group type: EXPERIMENTAL
Intervention: Fungal keratitis treatment
Number of subjects: 150
Study: 34840296

Group type: EXPERIMENTAL
Intervention: Unroofing curettage
Number of subjects: 278

Group type: COMPARATOR
Intervention: Modified Limberg flap
Number of subjects: 278
Study: 34840564

Group type: EXPERIMENTAL
Intervention: Characteristics of skin and hair of pregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin microbiome interactions
Number of subjects: 0
Study: 34840651

Group type: EXPERIMENTAL
Intervention: Oral glutathione supplement (L-glutathione, ascorbic acid, alpha-lipoic acid, zinc as zinc aspartate)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 83
Study: 34840720

Group type: EXPERIMENTAL
Intervention: Talazoparib (0.1-2.0 mg once daily)
Number of subjects: 33
Study: 34840869

Group type: EXPERIMENTAL
Intervention: Real-time nurse interpretation of quantitative EEG (qEEG)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nurse time to seizure detection
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Inaccurate nurse interpretation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall performance of nurse interpretation of qEEG
Number of subjects: 109
Study: 34841093

Group type: EXPERIMENTAL
Intervention: PIRATES approach (intensity-modulated proton therapy, mid-treatment hybrid hyper-fractionation, MRI-guided mid-treatment boost volume adaptation, iso-effective restricted organ-at-risk dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIRATES approach
Number of subjects: 0
Study: 34841420

Group type: EXPERIMENTAL
Intervention: Video Telehealth for HIV care during COVID-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34841462

Group type: EXPERIMENTAL
Intervention: Short, fully hydroxyapatite-coated titanium stem (collared and collarless versions)
Number of subjects: 50
Study: 34841945

Group type: EXPERIMENTAL
Intervention: Streamlined Care (rapid linkage to care and ART start, 3-monthly refills, viral load counseling, patient-centered care provision)
Number of subjects: 0
Study: 34842060

Group type: EXPERIMENTAL
Intervention: Virtual group therapy intervention (8 sessions over 4 weeks)
Number of subjects: 20
Study: 34842444

Group type: EXPERIMENTAL
Intervention: Cleaner-burning stove intervention
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Higher early life HAP exposure
Number of subjects: 1144
Study: 34842538

Group type: EXPERIMENTAL
Intervention: Social media intervention (monitoring cancer-specific posts on Twitter)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Social media intervention (engagement with outreach messages)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Social media intervention (request for more information)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Social media intervention (setup of prescreening)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Social media intervention (transfer for further screening)
Number of subjects: 434
Study: 34842546

Group type: EXPERIMENTAL
Intervention: Remote GDMT titration intervention
Number of subjects: 16
Study: 34842549

Group type: EXPERIMENTAL
Intervention: 4-week digital self-compassion intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 34842557

Group type: EXPERIMENTAL
Intervention: Predictive models built using methods from computational models of decision-making, combining objective data from a fitness tracker with personality traits and modeling from decision-making games delivered via a mobile app
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task administered via a web app
Number of subjects: 200
Study: 34842563

Group type: EXPERIMENTAL
Intervention: PARENT intervention (Parent Coach-led model of well-child care)
Number of subjects: 916
Study: 34843044

Group type: EXPERIMENTAL
Intervention: Sapanisertib (3 mg QD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sapanisertib (QD arm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sapanisertib (QW arm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sapanisertib
Number of subjects: 28
Study: 34843370

Group type: EXPERIMENTAL
Intervention: Mindfulness-based attention module
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other training modules (not specified)
Number of subjects: 0
Study: 34843401

Group type: EXPERIMENTAL
Intervention: Poziotinib (16 mg) once daily
Number of subjects: 90
Study: 34843469

Group type: EXPERIMENTAL
Intervention: Fractional-dose 17DD-YF vaccine in ARD patients
Number of subjects: 318
Study: 34843529

Group type: EXPERIMENTAL
Intervention: HCF-level stigma-reduction intervention
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard of care control arm
Number of subjects: 216
Study: 34843602

Group type: EXPERIMENTAL
Intervention: Adenoviral vector immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA/rAd5 and rAd35/rAd5 regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pox-viral vectors
Number of subjects: 0
Study: 34843666

Group type: EXPERIMENTAL
Intervention: pr/pb CAPA
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Age >62 years
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Treatment with dexamethasone and anti-IL-6
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Long duration of mechanical ventilation (>14 days)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Overall ICU mortality in patients with pr/pb CAPA
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Age >62 years (adjusted for candidaemia)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Solid organ transplantation (adjusted for candidaemia)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: pr/pb CAPA (adjusted for candidaemia)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Other pr/pb IFIs
Number of subjects: 509
Study: 34844152

Group type: EXPERIMENTAL
Intervention: MDD-PRS (Polygenic Risk Score for Major Depressive Disorder)
Number of subjects: 3637

Group type: EXPERIMENTAL
Intervention: MDD-PRS
Number of subjects: 3637

Group type: EXPERIMENTAL
Intervention: SCZ-PRS (Polygenic Risk Score for Schizophrenia)
Number of subjects: 3637
Study: 34844255

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 102
Study: 34844283

Group type: EXPERIMENTAL
Intervention: Insulin therapy guided by continuous glucose monitoring systems (CGMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin therapy guided by other forms of glucose data collection
Number of subjects: 0
Study: 34844422

Group type: EXPERIMENTAL
Intervention: Moderate hyperglycemia (serum glucose levels ≥140 mg/dL-<180)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Severe hyperglycemia (serum glucose levels ≥180 mg/dL)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Persistent hyperglycemia (either moderate or severe)
Number of subjects: 1000
Study: 34844606

Group type: EXPERIMENTAL
Intervention: Dietary intakes of vitamin C
Number of subjects: 7766

Group type: EXPERIMENTAL
Intervention: Dietary intakes of vitamin B9
Number of subjects: 7766

Group type: EXPERIMENTAL
Intervention: Dietary intakes of vitamin K
Number of subjects: 7766

Group type: EXPERIMENTAL
Intervention: Dietary intakes of fibers
Number of subjects: 7766

Group type: EXPERIMENTAL
Intervention: Dietary intakes of fruit and vegetables
Number of subjects: 7766

Group type: EXPERIMENTAL
Intervention: Dietary intakes of calcium
Number of subjects: 7766

Group type: EXPERIMENTAL
Intervention: Dietary intakes of dairy products
Number of subjects: 7766
Study: 34844641

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Magnesium supplements
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 34844770

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg (LAN 120 mg)
Number of subjects: 52
Study: 34844868

Group type: EXPERIMENTAL
Intervention: Radial access (RA)
Number of subjects: 3137

Group type: COMPARATOR
Intervention: Femoral access (FA)
Number of subjects: 3137
Study: 34844977

Group type: EXPERIMENTAL
Intervention: Etigilimab alone (0.3, 1.0, 3.0, 10.0, 20.0 mg/kg intravenously)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Etigilimab in combination with nivolumab (3.0, 10.0, 20.0 mg/kg etigilimab and 240 mg nivolumab)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adverse events reported in Phase 1a
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adverse events reported in Phase 1b
Number of subjects: 33
Study: 34844980

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anlotinib + PD-1 checkpoint inhibitor
Number of subjects: 0
Study: 34844993

Group type: EXPERIMENTAL
Intervention: High-Frequency 10-kHz Spinal Cord Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Treatments
Number of subjects: 0
Study: 34845071

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1,200 mg/m²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study: 34845080

Group type: EXPERIMENTAL
Intervention: 52-pathogen TaqMan array card (TAC)
Number of subjects: 100
Study: 34845082

Group type: EXPERIMENTAL
Intervention: PCV10 in a 0+1 schedule (at 12 months)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: PCV10 in a 1+1 schedule (at 2 and 12 months)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: PCV13 in a 0+1 schedule (at 12 months)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: PCV13 in a 1+1 schedule (at 2 and 12 months)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Single dose of PCV10 at 24 months (Control group)
Number of subjects: 2500
Study: 34845167

Group type: EXPERIMENTAL
Intervention: Peri-operative red blood cell transfusion
Number of subjects: 5609
Study: 34845300

Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal injections in vitrectomized eyes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal injections in non-vitrectomized eyes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ranibizumab intravitreal injections (both groups)
Number of subjects: 46
Study: 34845532

Group type: EXPERIMENTAL
Intervention: Poor sleep efficiency
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Later bedtime routines
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Deviation from usual sleep pattern
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal type
Number of subjects: 953
Study: 34845569

Group type: EXPERIMENTAL
Intervention: Pathway Meetings for Class I (Crisis, Imminent Risk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway Meetings for Class II (Crisis, Non-Imminent Risk)
Number of subjects: 0
Study: 34845868

Group type: EXPERIMENTAL
Intervention: Levetiracetam (1,000-2,000 mg daily in two divided doses during CCRT and adjuvant chemotherapy)
Number of subjects: 73
Study: 34845917

Group type: EXPERIMENTAL
Intervention: Unsupervised clustering (using generalized low rank modeling and K-means cluster analysis)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Cluster 1 (oldest/most comorbid)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Cluster 2 (youngest/multiethnic)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Cluster 4 (middle-aged/healthiest behaviors)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Cluster 3 (middle-aged/lowest medication adherence)
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Cluster membership vs. pooled cohort equations
Number of subjects: 1329
Study: 34845924

Group type: EXPERIMENTAL
Intervention: Dietary intake of EPA+DHA >200 mg/d
Number of subjects: 4067

Group type: COMPARATOR
Intervention: Dietary intake of EPA+DHA ≤50 mg/d
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Dietary intake of EPA+DHA per 100 mg/d
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 4067
Study: 34846602

Group type: EXPERIMENTAL
Intervention: Healthier dietary pattern characterized by consumption of vegetables and rye bread
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory diet (higher E-DII score)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Nutrient intakes (total fat, saturated fatty acids, trans fatty acids)
Number of subjects: 351
Study: 34846614

Group type: EXPERIMENTAL
Intervention: da Vinci R-TME
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Micro Hand S R-TME
Number of subjects: 134

Group type: COMPARATOR
Intervention: Laparoscopic TME (L-TME)
Number of subjects: 134
Study: 34846636

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study: 34847232

Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients treated with intensive chemotherapy
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with NPM1 mutations
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with mutations in the N-terminal SH2 domain
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with inv(3)(q21q26)/t(3;3)(q21;q26) and a normal karyotype
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with typical complex karyotype and core-binding factor AML
Number of subjects: 1725
Study: 34847547

Group type: EXPERIMENTAL
Intervention: Utah intracortical multi-electrode arrays
Number of subjects: 0
Study: 34847615

Group type: EXPERIMENTAL
Intervention: Family history of depression (FHD)
Number of subjects: 129
Study: 34848513

Group type: EXPERIMENTAL
Intervention: PRECIOUS-01 (PLGA-based immunomodulatory nanoparticles)
Number of subjects: 15
Study: 34848514

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-power diode laser
Number of subjects: 56
Study: 34848517

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training program targeting inhibitory skills
Number of subjects: 200

Group type: COMPARATOR
Intervention: Computerised neutral sensorial program (active control)
Number of subjects: 200
Study: 34848522

Group type: EXPERIMENTAL
Intervention: 330 mL/d of orange juice (OJ)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control drinks with and without hesperidin (approx. 200-215 mg)
Number of subjects: 42
Study: 34848527

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group 1 (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group 2 (not specified)
Number of subjects: 0
Study: 34848515

Group type: EXPERIMENTAL
Intervention: Preoperative diagnosis of SARS-CoV-2
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Age >80 years
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Preoperative diagnosis of dementia
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Kidney disease
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Increase to delay in surgery
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Type of anaesthetic given
Number of subjects: 1063
Study: 34848555

Group type: EXPERIMENTAL
Intervention: Asian/Asian British ethnicity
Number of subjects: 15227

Group type: EXPERIMENTAL
Intervention: Household overcrowding
Number of subjects: 15227

Group type: EXPERIMENTAL
Intervention: Any visits to/from other households in previous week
Number of subjects: 15227

Group type: EXPERIMENTAL
Intervention: Number of visits to indoor public places
Number of subjects: 15227

Group type: EXPERIMENTAL
Intervention: Frontline occupation excluding health/social care
Number of subjects: 15227

Group type: EXPERIMENTAL
Intervention: Raised body mass index (BMI) 25.0-30.0 kg/m²
Number of subjects: 15227

Group type: EXPERIMENTAL
Intervention: Atopic disease
Number of subjects: 15227
Study: 34848750

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 3 sessions of 30-min treadmill plus 2 sessions of 30-min strength training per week for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 18
Study: 34848836

Group type: EXPERIMENTAL
Intervention: High energy density (HED) food sensitization
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Low energy density (LED) food sensitization
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Interaction between HED and LED food sensitization
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Delay discounting (DD) moderation
Number of subjects: 201
Study: 34848949

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34849303

Group type: EXPERIMENTAL
Intervention: Compressor nebulization
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulization
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mesh nebulization
Number of subjects: 15
Study: 34849638

Group type: EXPERIMENTAL
Intervention: Tdap vaccinated (Boostrix®) mothers' infants
Number of subjects: 79
Study: 34849666

Group type: EXPERIMENTAL
Intervention: Pericarditis
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Myopericarditis
Number of subjects: 2533

Group type: COMPARATOR
Intervention: NSTEMI
Number of subjects: 2533
Study: 34849677

Group type: EXPERIMENTAL
Intervention: IL-6 concentrations ≥ median (17 ng/L)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: IL-6 concentrations
Number of subjects: 170
Study: 34849728

Group type: EXPERIMENTAL
Intervention: Theophylline (starting dose 300 mg b.i.d.)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control (historical cohort of untreated patients)
Number of subjects: 134
Study: 34849989

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 12 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 24 months
Number of subjects: 32
Study: 34850014

Group type: EXPERIMENTAL
Intervention: ECL-GADA positivity
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: ECL-GADA z-score titers
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: ECL-IAA positivity
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: RBA-GADA positivity
Number of subjects: 602

Group type: COMPARATOR
Intervention: RBA-IAA positivity
Number of subjects: 602
Study: 34850024

Group type: EXPERIMENTAL
Intervention: 4T cohort (Teamwork, Targets, Technology and Tight Control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 4T cohort with remote monitoring
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 4T cohort
Number of subjects: 135
Study: 34850052

Group type: EXPERIMENTAL
Intervention: Maternal HEI >57
Number of subjects: 108